NASHVILLE, Tenn., Feb. 15,
2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq:
CYRX) ("Cryoport" or the "Company"), a leading global provider of
innovative temperature-controlled supply chain solutions to the
life sciences industry focused on the pharmaceutical and cell and
gene therapy markets, today announced that the Company will report
financial results for the fourth quarter and year ended
December 31, 2022 on Thursday, February 23, 2023 after U.S. markets
close.
In addition to the earnings release, a document titled "Cryoport
Fourth Quarter and Full Year 2022 in Review", providing a review of
Cryoport's financial and operational performance and a general
business update, will be issued at 4:05 pm ET on Thursday, February 23, 2023. The document is
designed to be read in advance of the questions and answers
conference call and will be accessible at
http://ir.cryoport.com/events-and-presentations.
Cryoport management will host a conference call the same day at
5:00 pm ET. The conference call will
be in the format of a questions and answers session and will
address questions members of the investment community have
regarding the Company's reported results. A slide deck will
accompany the call.
Conference Call Information
Date:
|
Thursday, February 23,
2023
|
Time:
|
5:00 p.m. ET
|
Dial-in
numbers:
|
1-877-407-0789
(U.S.), 1-201-689-8562 (International)
|
Confirmation
code:
|
Request the "Cryoport
Call" or Conference ID: 13735986
|
Live
webcast:
|
'Investor Relations'
section at www.cryoport.com or click here.
Please allow 10 minutes
prior to the call to visit this site to download and install any
necessary audio software.
|
The questions and answers call will be recorded and available
approximately three hours after completion of the live event in the
Investor Relations section of the Company's website at
www.cryoport.com for a limited time. To access the replay of
the questions and answers click here. A dial-in replay of the call
will also be available to those interested, until March 2, 2023. To access the replay, dial
1-844-512-2921 (United States) or
1-412-317-6671 (International) and enter replay pin number:
13735986.
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is
a global leader in temperature-controlled supply chain solutions
for the life sciences industry supporting life-saving cell and gene
therapies across the research, clinical and commercial spectrum.
With 48 facilities in strategic locations covering the Americas,
EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform
provides mission-critical solutions, services, and products to the
Biopharma, Animal Health, and Reproductive Medicine markets
worldwide. In addition to its standard setting supply chain
solutions, Cryoport is the world's largest manufacturer of
cryogenic systems and one of the largest life science focused
specialty couriers.
For more information, visit www.cryoport.com or follow @cryoport
on Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this
press release which are not purely historical, including statements
regarding the Company's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to the
Company's industry, business, plans, strategy, acquisitions,
financial results and financial condition. It is important to note
that the Company's actual results could differ materially from
those in any such forward-looking statements. Factors that could
cause actual results to differ materially include, but are not
limited to, risks and uncertainties associated with the effect of
changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
discussed in the Company's Securities and Exchange Commission
("SEC") reports including, but not limited to, the Company's Annual
Report on Form 10-K for the three and twelve months ended
December 31, 2021 and any subsequent
filings with the SEC. The forward-looking statements contained in
this press release speak only as of the date hereof and the Company
cautions investors not to place undue reliance on these
forward-looking statements. Except as required by law, the Company
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-23-2023-301747273.html
SOURCE Cryoport, Inc.